We aim to further characterize additional VUS variants in MYCBP2. We are also interested in calculating the penetrance of MYCBP2-related neurodevelopmental delay.
Methods: us plan on using C.elegans as a model organism evaluated functional outcomes of VUS variants in vivo.
MYCBP2